Amneal Pharmaceuticals, Inc. AMRX Specialty — Gross Profit
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GrossProfit.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — gross profit.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s specialty — gross profit?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — gross profit of $90.25M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s specialty — gross profit changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s specialty — gross profit increased by 63.4% year-over-year, from $55.21M to $90.25M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — gross profit?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — gross profit has grown at a 11.2% compound annual growth rate (CAGR), from $184.76M to $282.59M.
- What does specialty — gross profit mean?
- Calculated as net revenue minus the cost of goods sold for the specialty segment, representing the core profitability of the products before operating expenses. It serves as a key measure of the segment's pricing power and production cost management.